Erste Group Bank Issues Optimistic Estimate for NVO Earnings

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank lifted their FY2027 earnings per share estimates for Novo Nordisk A/S in a research report issued on Tuesday, May 12th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $3.28 for the year, up from their prior estimate of $3.27. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.47 per share.

A number of other equities research analysts also recently weighed in on NVO. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research report on Tuesday, March 3rd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NVO opened at $44.24 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company has a market capitalization of $197.52 billion, a price-to-earnings ratio of 10.38, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The business has a 50 day moving average price of $39.95 and a two-hundred day moving average price of $46.54. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. Western Wealth Management LLC increased its holdings in Novo Nordisk A/S by 89.9% in the 1st quarter. Western Wealth Management LLC now owns 16,271 shares of the company’s stock valued at $598,000 after buying an additional 7,703 shares during the period. Alexander Labrunerie & CO. Inc. raised its stake in shares of Novo Nordisk A/S by 9.2% in the first quarter. Alexander Labrunerie & CO. Inc. now owns 12,077 shares of the company’s stock valued at $444,000 after acquiring an additional 1,019 shares during the last quarter. Strategic Planning Inc. raised its position in Novo Nordisk A/S by 2.4% in the 1st quarter. Strategic Planning Inc. now owns 72,366 shares of the company’s stock valued at $2,659,000 after purchasing an additional 1,713 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 53.4% in the first quarter. EverSource Wealth Advisors LLC now owns 8,364 shares of the company’s stock valued at $307,000 after buying an additional 2,912 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Novo Nordisk A/S by 3.2% during the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk expanded its obesity pipeline with updates on the AMAZE 12 Phase 3 trial and a new cagrilintide study, reinforcing its push to maintain leadership beyond current blockbuster products. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Positive Sentiment: The company also announced a share repurchase program, which can support earnings per share and signals management confidence in Novo Nordisk’s cash generation. Novo Nordisk A-S share repurchase programme
• Neutral Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Novo Nordisk, adding a modestly constructive analyst note but not a major catalyst on its own.
• Neutral Sentiment: News coverage highlighted Novo Nordisk’s plan to push obesity treatments globally, especially outside the U.S., where the company sees a major growth opportunity. Novo Nordisk’s next obesity battlefront: Winning beyond America
• Negative Sentiment: Investors remain focused on intensifying competition from Eli Lilly and other GLP-1 rivals, with articles noting the race to launch obesity pills globally and the risk of new entrants pressuring Novo Nordisk’s market share. GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
• Negative Sentiment: Citi tracking showed Wegovy pill prescriptions slipped week over week, even though the drug still leads competitors, suggesting momentum is strong but not uninterrupted. Novo Nordisk’s Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.